268 related articles for article (PubMed ID: 34331110)
21. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
Chiaranairungrot K; Kaewpreechawat K; Sajai C; Pagowong N; Sukarat N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L; Rattarittamrong E
Hematology; 2022 Dec; 27(1):813-819. PubMed ID: 35894859
[TBL] [Abstract][Full Text] [Related]
22. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F; Lazzarino M
Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
[TBL] [Abstract][Full Text] [Related]
23. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
24. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.
Ianotto JC; Curto-Garcia N; Lauermanova M; Radia D; Kiladjian JJ; Harrison CN
Haematologica; 2019 Aug; 104(8):1580-1588. PubMed ID: 30679326
[TBL] [Abstract][Full Text] [Related]
27. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
[TBL] [Abstract][Full Text] [Related]
28. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
29. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
30. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
31. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
33. Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
Ahmed AK; Youssef A; Skeik N
Ann Vasc Surg; 2017 Jul; 42():306.e5-306.e10. PubMed ID: 28259826
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet therapy in the management of myeloproliferative neoplasms.
Alvarez-Larrán A; Besses C
Curr Hematol Malig Rep; 2014 Dec; 9(4):319-23. PubMed ID: 25120015
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
36. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
37. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
[TBL] [Abstract][Full Text] [Related]
38. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcome in a cohort of young patients with polycythemia vera.
Ruggeri M; Finotto S; Fortuna S; Rodeghiero F
Intern Emerg Med; 2010 Oct; 5(5):411-3. PubMed ID: 20607450
[TBL] [Abstract][Full Text] [Related]
40. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
